BGI GENOMICS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 41.13 CNY | -0.19% |
|
+5.52% | -14.31% |
| 04-26 | BGI Genomics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 04-15 | BGI Genomics Co., Ltd. Proposes Final Cash Dividend for the Year 2023 | CI |
ETFs positioned on BGI Genomics Co., Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.36% | 2 M€ | -12.95% | - | |
| 0.07% | 11 M€ | +3.37% | ||
| 0.04% | 35 M€ | -5.85% | - | |
| 0.02% | 2 M€ | -.--% | ||
| 0.02% | 7 M€ | -.--% | - | |
| 0.00% | 4 M€ | -4.41% | - | |
| 0.00% | 2,808 M€ | +7.44% | - | |
| 0.00% | 441 M€ | +4.34% | - | |
| 0.00% | 149 M€ | +2.23% | - | |
| 0.00% | 34 M€ | +1.32% | - | |
| 0.00% | 7 M€ | +2.58% | - | |
| 0.00% | 15 M€ | +12.19% |
BGI Genomics Co., Ltd. is a leading provider of genomic and proteomic sequencing services primarily to academic institutions, pharmaceutical companies and healthcare providers. The company also provides genomic solutions for biomarker research and development, screening for some of the trisomies present at birth (trisomy 21, trisomy 18 and trisomy 13) and solutions for neo-antigen identification for immuno-oncology research.
Calendar
2024-05-09
- Annual General Meeting
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -14.31% | 2.16B | |
| -18.60% | 11.03B | |
| +54.06% | 3.5B | |
| -32.38% | 2.23B | |
| -26.84% | 1.54B | |
| +32.29% | 1.12B | |
| -3.28% | 737M | |
| -22.42% | 477M | |
| -41.94% | 411M | |
| +17.30% | 342M |
- Stock Market
- Equities
- 300676 Stock
- Funds and ETFs BGI Genomics Co., Ltd.
